CN111491632A - 癌症治疗药 - Google Patents

癌症治疗药 Download PDF

Info

Publication number
CN111491632A
CN111491632A CN201880082290.5A CN201880082290A CN111491632A CN 111491632 A CN111491632 A CN 111491632A CN 201880082290 A CN201880082290 A CN 201880082290A CN 111491632 A CN111491632 A CN 111491632A
Authority
CN
China
Prior art keywords
cancer
cyclodextrin
injection
acid
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880082290.5A
Other languages
English (en)
Chinese (zh)
Inventor
远藤仁
古濑纯司
冈安勋
迈克尔·F·温普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
J Pharma Co Ltd
Original Assignee
J Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J Pharma Co Ltd filed Critical J Pharma Co Ltd
Publication of CN111491632A publication Critical patent/CN111491632A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
CN201880082290.5A 2017-12-28 2018-08-01 癌症治疗药 Pending CN111491632A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017-253385 2017-12-28
JP2017253385 2017-12-28
PCT/JP2018/028887 WO2019130637A1 (ja) 2017-12-28 2018-08-01 がん治療薬

Publications (1)

Publication Number Publication Date
CN111491632A true CN111491632A (zh) 2020-08-04

Family

ID=67066788

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880082290.5A Pending CN111491632A (zh) 2017-12-28 2018-08-01 癌症治疗药

Country Status (10)

Country Link
US (1) US12458628B2 (enExample)
EP (1) EP3733175B1 (enExample)
JP (4) JP6546367B1 (enExample)
KR (1) KR102377742B1 (enExample)
CN (1) CN111491632A (enExample)
BR (1) BR112020012766A2 (enExample)
CA (1) CA3083343C (enExample)
ES (1) ES2960392T3 (enExample)
MX (1) MX2020006678A (enExample)
WO (1) WO2019130637A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7369378B2 (ja) * 2017-11-07 2023-10-26 ジェイファーマ株式会社 抗がん剤及びがんを治療するための医薬組成物
WO2020232227A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
CN112336859A (zh) * 2019-08-06 2021-02-09 上海绿谷制药有限公司 通过抑制t细胞摄取氨基酸治疗阿尔茨海默病的方法
EP4090329A2 (en) * 2020-01-17 2022-11-23 Tyme, Inc. Tyrosine derivatives for modulating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
WO2022102687A1 (ja) * 2020-11-11 2022-05-19 ジェイファーマ株式会社 がん治療剤
CN120359050A (zh) 2023-01-16 2025-07-22 J制药股份有限公司 胆道癌治疗剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008081537A1 (ja) * 2006-12-28 2008-07-10 Human Cell Systems, Inc. Ｌａｔ１阻害活性を有する芳香族アミノ酸誘導体、それを含有するｌａｔ１阻害活性剤及びその製造方法
CN105392498A (zh) * 2014-05-15 2016-03-09 J制药股份有限公司 抗恶性肿瘤剂组合物
JP2017155023A (ja) * 2016-03-04 2017-09-07 ジェイファーマ株式会社 Ｌａｔ１阻害活性を有する芳香族アミノ酸誘導体を含有する注射剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7369378B2 (ja) 2017-11-07 2023-10-26 ジェイファーマ株式会社 抗がん剤及びがんを治療するための医薬組成物
CN114364381A (zh) 2019-08-30 2022-04-15 J制药股份有限公司 用于具有特定的基因标志的患者的癌症治疗用药物组合物
WO2022102687A1 (ja) 2020-11-11 2022-05-19 ジェイファーマ株式会社 がん治療剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008081537A1 (ja) * 2006-12-28 2008-07-10 Human Cell Systems, Inc. Ｌａｔ１阻害活性を有する芳香族アミノ酸誘導体、それを含有するｌａｔ１阻害活性剤及びその製造方法
CN105392498A (zh) * 2014-05-15 2016-03-09 J制药股份有限公司 抗恶性肿瘤剂组合物
JP2017155023A (ja) * 2016-03-04 2017-09-07 ジェイファーマ株式会社 Ｌａｔ１阻害活性を有する芳香族アミノ酸誘導体を含有する注射剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOJI ODA等: "L-Type amino acid transporter 1 inhibitors inhibit tumor cell growth", 《CANCER SCIENCE》 *
NOBUYUKI YANAGISAWA等: "High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas", 《CANCER MEDICINE》 *

Also Published As

Publication number Publication date
CA3083343A1 (en) 2019-07-04
US20200405695A1 (en) 2020-12-31
JP2020073586A (ja) 2020-05-14
JP2023101705A (ja) 2023-07-21
CA3083343C (en) 2022-04-26
KR102377742B1 (ko) 2022-03-22
US12458628B2 (en) 2025-11-04
JPWO2019130637A1 (ja) 2019-12-26
EP3733175A1 (en) 2020-11-04
EP3733175A4 (en) 2021-08-18
BR112020012766A2 (pt) 2020-12-01
MX2020006678A (es) 2020-08-31
EP3733175B1 (en) 2023-10-04
JP6546367B1 (ja) 2019-07-17
WO2019130637A1 (ja) 2019-07-04
JP7541400B2 (ja) 2024-08-28
ES2960392T3 (es) 2024-03-04
JP6734971B2 (ja) 2020-08-05
JP2019151672A (ja) 2019-09-12
KR20200101960A (ko) 2020-08-28

Similar Documents

Publication Publication Date Title
CN111491632A (zh) 癌症治疗药
EP2508207B1 (en) Nanoparticles loaded with chemotherapeutic antitumoral Drug
US20010018445A1 (en) Pharmaceutical composition for the treatment of hepatocellular carcinoma
AU2008222592B2 (en) Compositions and methods for delivery of anti-cancer agents
CN103370066B (zh) 用于治疗癌症的包含威罗菲尼和干扰素的组合疗法
US11141421B2 (en) Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
JP2016508138A (ja) カバジタキセル組成物
JP2025011312A (ja) ｐ－ボロノフェニルアラニンを含有する注射液剤の析出防止方法
JP2004504346A (ja) 骨転移の治療におけるリン酸エストラムスチンの使用
TW202000207A (zh) 膀胱癌用抗腫瘤劑及膀胱癌的處置方法
EP3873510B1 (en) Thiostrepton and vitamin e-tpgs for treating cancer
CN1374858A (zh) 具有改进药理学性质的非肠胃道使用的雌莫司汀磷酸盐制剂
US8273721B2 (en) Combination treatment for bladder cancer
CN115444938A (zh) cGAS抑制剂与化疗药物联合在制备治疗肺癌药物中的用途
HK40055088A (en) Thiostrepton and vitamin e-tpgs for treating cancer
HK40055088B (en) Thiostrepton and vitamin e-tpgs for treating cancer
CN111658645A (zh) R848或r848与索拉非尼联合用于治疗癌症的药物组合物和用途
EP1226824A1 (en) Use of thalidomide for the treatment of hepatocellular carcinoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination